drugset / Trial / NCT00416702

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

NCT00416702

Phase 1 Completed 32 enrolled Novartis
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects

Timeline

Start
2006-11
Primary completion
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 600 ug

Indications